(Reuters) – Ionis Pharmaceuticals said on Monday its therapy for the treatment of a rare genetic disease met the main goal in a late-stage trial.
(Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath)
(Reuters) – Ionis Pharmaceuticals said on Monday its therapy for the treatment of a rare genetic disease met the main goal in a late-stage trial.
(Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath)
Comments